News & Updates
Filter by Specialty:
Group CBT with interoceptive exposure safe, effective for drug-refractory IBS
Group cognitive behavioural therapy (GCBT) with interoceptive exposure (IE) is not only safe and effective but also an efficient treatment option for individuals with drug-refractory irritable bowel syndrome (IBS), according to a Japan study.
Group CBT with interoceptive exposure safe, effective for drug-refractory IBS
18 Apr 2022
Early endoscopy effective for UGIB in acute coronary syndrome patients
In patients with recent acute coronary syndrome (ACS), early endoscopy (EE) for upper gastrointestinal bleeding (UGIB) is superior to non-EE, leading to better rates of bleeding control, lower rates of rebleeding, and less need for transfusion, reports a recent study.
Early endoscopy effective for UGIB in acute coronary syndrome patients
13 Apr 2022
Sham acupuncture improves symptoms, QoL in functional dyspepsia
Both sham manual acupuncture (MA) and sham electroacupuncture (EA) result in better symptoms and quality of life (QoL) scores among individuals with functional dyspepsia (FD) without affecting objective outcomes, a study has found. This finding underscores the importance of sham controls in acupuncture therapy clinical trials.
Sham acupuncture improves symptoms, QoL in functional dyspepsia
13 Apr 2022
Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab
Ustekinumab is well tolerated and proves to be effective in the second-line treatment of patients with Crohn’s disease, according to real-world data from the Cross Pennine II study. Furthermore, while clinical remission appears to occur sooner with ustekinumab than with vedolizumab, the two drugs perform comparably at maintaining remission over 12 months.
Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab
12 Apr 2022
Hepatitis B virus treatment rates still low among eligible patients
Administration rates of antiviral therapy remain low among treatment-eligible patients with chronic hepatitis B virus (CHB) and among CHB patients without human immunodeficiency virus (HIV), reveals a recent study.